Availability (in Japan)
10 or more
(In Japan at 00:05,
Dec 5, 2024 in JST)
Size
200 µL (1 mg/mL)
Data | |||||
---|---|---|---|---|---|
Clonality | Monoclonal | Clone | 235-1 | ||
Isotype (Immunized Animal) | Mouse IgG2aκ | ||||
Applications |
|
||||
Immunogen (Antigen) | Carrier protein-conjugated trimethylguanosine (m3G/TMG) | ||||
Storage buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 | ||||
Storage temp. | -20°C | Conjugate | Unlabeled | Manufacturer | MBL |
Alternative names | N2,N2,7-Trimethylguanosine, m2,2,7G | ||||
Background | Small nuclear RNA (snRNA) is known to be involved in pre-mRNA splicing as an RNA component of snRNP. 2,2,7-trimethylated guanosine (m3G/TMG) is a modified nucleoside at the 5’-cap site of U snRNAs except for U6 snRNA. Shortly after transcription, 7-methylguanosine (m7G), called cap structure, is added to 5’-end of newly synthesized U snRNA and m7G-capped U snRNA is exported to the cytoplasm. The m7G-cap is converted to m3G-cap, which is a hypermethylated structure of 5’-end, by cytoplasmic catalytic protein TSG1 and the m3G-capped U snRNA forms snRNP with Sm proteins in the cytoplasm, followed by entry into the nucleus. The m3G-capped snRNP plays a role in regulation of pre-mRNA splicing as a part of spliceosome in nucleus. It is also reported that U3 and U8 snoRNA, localized to Cajal body during RNP biogenesis, possess m3G-cap structure. | ||||
Related products | RN1005 RIP-Assay Kit for microRNA D347-3 Anti-Pseudouridine mAb D345-3 Anti-1-methyladenosine (m1A) mAb D346-3 Anti-5-methylcytidine (m5C) mAb PM077 Anti-5-hydroxymethylcytosine (5hmC) pAb MI-11-3 Anti-Bromodeoxyuridine mAb MI-11-5 Anti-Bromodeoxyuridine mAb-PE RN095PW Anti-SNRNP200 pAb M218-3 Anti-5-hydroxymethylcytosine (5hmC) mAb M227-3 Anti-Digoxigenin (DIG) mAb M228-3 Anti-FITC mAb RN077PW Anti-SMN1 pAb RN124PW Anti-RNMT (Human) pAb RN016M Anti-7-methylguanosine (m7G)-Cap mAb RN017M Anti-7-methylguanosine (m7G) mAb PM098 Anti-Inosine pAb |
||||
References |
|
||||
Product category |
|